SHILPAMED

Shilpa Medicare Share Price

₹768.95 +3.6 (0.47%)

28 Dec, 2024 03:15

SIP TrendupStart SIP in SHILPAMED

Start SIP

Performance

  • Low
  • ₹760
  • High
  • ₹779
  • 52 Week Low
  • ₹313
  • 52 Week High
  • ₹960
  • Open Price₹770
  • Previous Close₹765
  • Volume373,196

Investment Returns

  • Over 1 Month -13.45%
  • Over 3 Month -7.06%
  • Over 6 Month + 30.73%
  • Over 1 Year + 116.21%
SIP Lightning

Smart Investing Starts Here Start SIP with Shilpa Medicare for Steady Growth!

Invest Now

Shilpa Medicare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 123.1
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 7,520
  • P/B Ratio
  • 4.2
  • Average True Range
  • 36.8
  • EPS
  • 5.87
  • Dividend Yield
  • 0
  • MACD Signal
  • -14.62
  • RSI
  • 34.82
  • MFI
  • 49.89

Shilpa Medicare Financials

Shilpa Medicare Technicals

EMA & SMA

Current Price
₹768.95
+ 3.6 (0.47%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹819.39
  • 50 Day
  • ₹830.67
  • 100 Day
  • ₹793.43
  • 200 Day
  • ₹699.06

Resistance and Support

769.15 Pivot Speed
  • R3 798.30
  • R2 788.65
  • R1 778.80
  • S1 759.30
  • S2 749.65
  • S3 739.80

What's your outlook on Shilpa Medicare?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Shilpa Medicare Ltd. is a leading Indian pharmaceutical company specializing in the development and manufacturing of generic drugs, APIs, and biotechnology products. Focused on oncology and other therapeutic areas, it aims to provide affordable healthcare solutions globally.

Shilpa Medicare Limited has an operating revenue of Rs. 1,214.48 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 5% is okay, ROE of 1% is fair but needs improvement. The company has a reasonable debt to equity of 31%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 13% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 20% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Shilpa Medicare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-08 Quarterly Results
2024-05-23 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-10 Quarterly Results

Shilpa Medicare F&O

Shilpa Medicare Shareholding Pattern

44.33%
5.09%
1.61%
9.59%
0%
23.94%
15.44%

About Shilpa Medicare

  • NSE Symbol
  • SHILPAMED
  • BSE Symbol
  • 530549
  • Managing Director
  • Mr. Vishnukant C Bhutada
  • ISIN
  • INE790G01031

Similar Stocks to Shilpa Medicare

Shilpa Medicare FAQs

Shilpa Medicare share price is ₹768 As on 28 December, 2024 | 03:01

The Market Cap of Shilpa Medicare is ₹7519.6 Cr As on 28 December, 2024 | 03:01

The P/E ratio of Shilpa Medicare is 123.1 As on 28 December, 2024 | 03:01

The PB ratio of Shilpa Medicare is 4.2 As on 28 December, 2024 | 03:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23